GlassScriptPhysician profile
Anjuman Ara
NPI 1184657314
$1,307.12
in general payments reported to CMS, 2019-2025
22 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $84.75 · 2021: $105 · 2022: $280 · 2023: $264 · 2024: $189 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $419.08 | 2019-2025 | Trelegy Ellipta |
| Smith+Nephew, INC. | $119.44 | 2019-2024 | Collagenase Santyl |
| Lilly USA, LLC | $106.07 | 2019-2025 | Jardiance |
| Abbvie INC. | $95.87 | 2022-2023 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $69.71 | 2019-2025 | Rybelsus, Ozempic |
| Mannkind Corporation | $59.40 | 2022 | |
| Acera Surgical, INC. | $54.50 | 2025 | Restrata Wound Matrix |
| Kerecis Limited | $52.15 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bioventus LLC | $46.61 | 2022-2023 | |
| Reprise Biomedical, INC. | $34.61 | 2024 | Miro3d |
| Astrazeneca Pharmaceuticals LP | $27.67 | 2022-2024 | |
| Tactile Systems Technology INC | $27.59 | 2019-2021 | |
| Convatec INC. | $25.25 | 2025 | |
| Innocoll Pharmaceuticals Limited | $22.05 | 2021 | |
| Dexcom, INC. | $21.95 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $20.02 | 2021 | |
| Kci USA, INC. | $18.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.67 | 2025 | Jardiance |
| Nabriva Therapeutics, Plc | $17.95 | 2020 | |
| Pfizer INC. | $17.74 | 2020 | |
| Daiichi Sankyo INC. | $16.01 | 2019 | |
| Phadia US INC. | $15.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjuman Ara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.